Last reviewed · How we verify

The ropivacaine group

Beijing Tiantan Hospital · FDA-approved active Small molecule

The ropivacaine group is a Local anesthetic (amide) Small molecule drug developed by Beijing Tiantan Hospital. It is currently FDA-approved for Local and regional anesthesia for surgery and acute pain management, Peripheral nerve blocks, Epidural anesthesia.

Ropivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials.

Ropivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials. Used for Local and regional anesthesia for surgery and acute pain management, Peripheral nerve blocks, Epidural anesthesia.

At a glance

Generic nameThe ropivacaine group
SponsorBeijing Tiantan Hospital
Drug classLocal anesthetic (amide)
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia / Pain Management
PhaseFDA-approved

Mechanism of action

Ropivacaine reversibly inhibits sodium influx into nerve fibers, which stabilizes the neuronal membrane and prevents depolarization. This action blocks conduction of sensory, motor, and autonomic nerve impulses in a dose-dependent manner. It is an amide-type local anesthetic with a long duration of action and lower cardiotoxicity compared to some other local anesthetics.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about The ropivacaine group

What is The ropivacaine group?

The ropivacaine group is a Local anesthetic (amide) drug developed by Beijing Tiantan Hospital, indicated for Local and regional anesthesia for surgery and acute pain management, Peripheral nerve blocks, Epidural anesthesia.

How does The ropivacaine group work?

Ropivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials.

What is The ropivacaine group used for?

The ropivacaine group is indicated for Local and regional anesthesia for surgery and acute pain management, Peripheral nerve blocks, Epidural anesthesia.

Who makes The ropivacaine group?

The ropivacaine group is developed and marketed by Beijing Tiantan Hospital (see full Beijing Tiantan Hospital pipeline at /company/beijing-tiantan-hospital).

What drug class is The ropivacaine group in?

The ropivacaine group belongs to the Local anesthetic (amide) class. See all Local anesthetic (amide) drugs at /class/local-anesthetic-amide.

What development phase is The ropivacaine group in?

The ropivacaine group is FDA-approved (marketed).

What are the side effects of The ropivacaine group?

Common side effects of The ropivacaine group include Hypotension, Bradycardia, Nausea, Headache, Dizziness, Systemic toxicity (CNS and cardiac effects at high doses).

What does The ropivacaine group target?

The ropivacaine group targets Voltage-gated sodium channels and is a Local anesthetic (amide).

Related